This week's IBD research digest: drug access barriers are shaping treatment decisions more than clinical evidence. Real-world data that validates what patients experience with prior auth and step therapy.
Plus: NSAID findings that challenge conventional wisdom.
10 stories, May 4–10. Clinical stage + practical implications marked for each.
The hardest part of a new Crohn's drug isn't side effects, the injections, or the cost.
It's the not knowing.
A structured approach to self-assessment during treatment transitions — daily symptom logging, tracking "quiet wins" (sleeping through the night, eating without anxiety), and watching systemic signals beyond the gut.
"Breakthrough treatment for Crohn's!" — I've been reading those headlines since 2002.
IBD Movement is where I break down what the research actually means for patients — from someone who's lived it for 23 years.
ibdmovement.com/?utm_source=mastodon
